Navigation Links
Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders
Date:4/15/2008

ROCHESTER, Minn., April 15, 2008 /PRNewswire-USNewswire/ -- Three new Mayo Clinic studies find that REM (rapid eye movement) sleep behavior disorder is associated with anxiety, apathy, lower scores in attention and executive functioning, as well as symptoms of Parkinson's disease. The findings will be presented at the American Academy of Neurology Annual Meeting in Chicago on April 15.

People who have REM sleep behavior disorder (RBD) appear to act out their dreams, which often are unpleasant and violent. Acting out is caused by a loss of normal muscle paralysis in REM sleep, the stage of sleep when dreaming occurs. A relatively uncommon condition, RBD is estimated to affect approximately 0.5 percent of the population, but occurs most frequently in older males.

"Previous studies have shown that some patients with RBD subsequently develop dementia and/or parkinsonism, which typically reflects a neurodegenerative disorder such as Lewy body dementia or Parkinson's disease," says Bradley Boeve, M.D., an author of these studies and a neurologist at Mayo Clinic. "Our knowledge on the RBD-neurodegenerative disease association is largely based on studies focused on single patients, or small groups of patients, with RBD. There are very few studies that have been carried out on RBD on a large scale. Plus, we currently aren't able to identify which patients with RBD will later develop other features of a neurodegenerative disease and which patients with RBD will not. We therefore sought to study RBD and other features commonly associated with Lewy body dementia and Parkinson's disease in a large population-based study."

Dr. Boeve and a team of Mayo Clinic physicians set out to determine whether cognitively-normal individuals with RBD have other features commonly associated with Lewy body dementia and Parkinson's disease. They identified 765 individuals, ages 70 to 89, who underwent a battery of scales and tests. Using the Mayo sleep questionnaire, a validated screening measure for RBD, researchers determined that 8 percent of these individuals had probable RBD. Twenty-one percent with probable RBD had anxiety and 11.5 percent had apathy (compared with 8 percent and 4 percent, respectively, for individuals without RBD). Those individuals with RBD had significantly lower scores on neuropsychological measures of attention and executive functioning, such as concentration, decision making, and higher-order problem solving. Additionally, researchers found that 1.8 percent of the individuals had both RBD and parkinsonism.

"There is currently no treatment to delay the onset or prevent dementia or parkinsonism in patients with RBD who are destined to develop these neurologic problems in the future," says Dr. Boeve. "Our ultimate goal is to use therapies that would delay the onset or prevent these problems from ever developing in patients who have a form of RBD that reflects an evolving neurodegenerative disease. However, much more research is needed to get to that point."

Dr. Boeve and his team will continue to study this group of patients to better understand how RBD is associated with neurodegenerative disease. Other members of the Mayo Clinic research team included Jennifer Molano, M.D., Ebru Mihci, M.D., Rosebud Roberts, M.B.Ch.B., Yonas Geda, M.D., David Knopman, M.D., Eric Tangalos, M.D., Glenn Smith, Ph.D., Robert Ivnik, Ph.D., Ruth Cha, V. Shane Pankratz, Ph.D., Michael Silber, M.B.Ch.B., Tanis Ferman, Ph.D., and Ronald Petersen, M.D., Ph.D.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
2. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
3. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
4. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
5. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
6. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
7. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Presentation of HeartWare Clinical Results
10. Clinically Proven Treatment Offers Help to Rosacea Sufferers
11. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... While it’s often important to take certain medications during the ... Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL ... it eliminates the need to turn on a light when taking medication during the ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
Breaking Medicine News(10 mins):